Pfizer has enjoyed an unprecedented rise in sales since the global rollout of its Covid-19 vaccine, developed with Germany's BioNTech. Vaccine sales have, however, started to slow since last year, and BioNTech shares fell sharply in Monday trade when its latest earnings fell short of expectations. BioNTechMeanwhile, shares in BioNTech in Frankfurt trade fell as lagging Covid-19 vaccine orders held sales and profit short of analysts’ expectations. BioNTech and its partner Pfizer are counting on an Omicron-adapted vaccine to reinvigorate sales for the rest of the year. Sales fell to €3.2bn.

Source: Irish Examiner August 09, 2022 20:38 UTC